Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells

By sjmartinez • March 13, 2023

Li S, Wang CS, Montel-Hagen A, Chen HC, Lopez S, Zhou O, Dai K, Tsai S, Satyadi W, Botero C, Wong C, Casero D, Crooks GM, Seet CS. Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells. Cell Rep. 2023 Mar 10;42(3):112241. doi: 10.1016/j.celrep.2023.112241. Epub ahead of print. PMID: 36906850.

Tags: adoptive cell therapy, cancer immunotherapy, chimeric antigen receptor, CP, Hematology/Oncology, Immunology, innate lymphoid cells, pluripotent stem cells, Publications, Stem cell research, T cell development

Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma

Sullivan RJ, Tsai KK, Pavlick AC, Buchbinder EI, Agarwala SS, Ribas A, Jansson J, Rossiter G, Olszanski AJ. Phase 1b Study of Tovorafenib, Plozalizumab or[...]

ASCO State of Cancer Care in America Special Report 2025: Access to Cancer Clinical Trials in the United States

Balogh EP, Levit LA, Unger JM, Accordino MK, Chism DD, Kirkwood MK, Parsons HM, Patel MI, Peppercorn JM, Polite BN, Sedrak MS, Sharma P, Subbiah[...]

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses

Foster L, Anderson LD Jr, Chung A, Chaulagain CP, Pettijohn E, Cowan AJ, Costello C, Larson S, Sborov DW, Shain KH, Silbermann R, Voorhees P,[...]